Genzyme

Genzyme
Tim Pierce · Public domain · source
Name	Genzyme
Type	Subsidiary
Industry	Biotechnology
Founded	1981
Founder	George M. Whitesides, Henry Blair
Headquarters	Cambridge, Massachusetts
Key people	Henri A. Termeer, David Meeker
Parent	Sanofi

Genzyme is a biotechnology company that was founded in 1981 by George M. Whitesides and Henry Blair in Cambridge, Massachusetts. The company was acquired by Sanofi in 2011 and has since become a subsidiary, operating under the leadership of David Meeker. Genzyme has a long history of developing and marketing innovative treatments for rare and debilitating diseases, often in collaboration with organizations such as the National Institutes of Health and the European Medicines Agency. The company's work has been recognized with numerous awards, including the National Medal of Technology and the Albany Medical Center Prize in Medicine and Biomedical Research.

● History

Genzyme was founded in 1981 by George M. Whitesides and Henry Blair with the goal of developing and marketing innovative treatments for rare and debilitating diseases. The company's early success was driven by the development of Ceredase, a treatment for Gaucher's disease that was approved by the Food and Drug Administration in 1991. This was followed by the approval of Cerezyme in 1994, which became a major commercial success for the company. Genzyme's growth and expansion were also influenced by its collaborations with other companies, such as Bayer and Pfizer, as well as its involvement in industry organizations like the Biotechnology Innovation Organization and the Pharmaceutical Research and Manufacturers of America. The company's history has also been marked by significant events, including the IPO in 1986 and the acquisition by Sanofi in 2011, which was facilitated by Goldman Sachs and Morgan Stanley.

● Products and Services

Genzyme's product portfolio includes a range of treatments for rare and debilitating diseases, such as Lysosomal storage disorders and Multiple sclerosis. The company's products, including Aldurazyme and Fabrazyme, have been approved by regulatory agencies such as the European Medicines Agency and the Food and Drug Administration. Genzyme also offers a range of services, including Genetic testing and Patient support programs, which are often provided in collaboration with organizations such as the National Organization for Rare Disorders and the European Organisation for Rare Diseases. The company's products and services have been recognized with numerous awards, including the Prix Galien and the Pharmaceutical Research and Manufacturers of America's Discoverer's Award.

● Research and Development

Genzyme's research and development efforts are focused on the discovery and development of new treatments for rare and debilitating diseases. The company's research programs are often conducted in collaboration with academic institutions, such as Harvard University and Massachusetts Institute of Technology, as well as other companies, like Regeneron Pharmaceuticals and Biogen. Genzyme's research has led to the development of new technologies, such as Gene therapy and Stem cell therapy, which have the potential to treat a range of diseases, including Cancer and Neurodegenerative disorders. The company's research has also been recognized with numerous awards, including the Lasker Award and the Breakthrough Prize in Life Sciences.

● Corporate Affairs

Genzyme is a subsidiary of Sanofi, a multinational pharmaceutical company headquartered in Paris, France. The company is led by David Meeker, who has been instrumental in shaping the company's strategy and direction. Genzyme's corporate affairs are also influenced by its involvement in industry organizations, such as the Biotechnology Innovation Organization and the Pharmaceutical Research and Manufacturers of America. The company has also been recognized for its commitment to corporate social responsibility, including its support for organizations such as the United Way and the American Red Cross.

● Therapeutic Areas

Genzyme's therapeutic areas of focus include Lysosomal storage disorders, Multiple sclerosis, and Oncology. The company's products and research programs are designed to address the unmet medical needs of patients with these diseases, often in collaboration with organizations such as the National Multiple Sclerosis Society and the American Cancer Society. Genzyme's work in these therapeutic areas has led to the development of new treatments, such as Aldurazyme and Lemtrada, which have been approved by regulatory agencies such as the Food and Drug Administration and the European Medicines Agency. The company's research has also been recognized with numerous awards, including the Warren Alpert Foundation Prize and the American Association for Cancer Research's Team Science Award.

Category:Biotechnology companies